Open Peer Commentary to "Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019".

Alzheimers Dement · 2021 · PMC8043968 · PMID 33135288

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

Although the number of patients included in the substudies is small, there was a dose‐related decrease of CSF phosphorylated tau (p‐tau) and a nonsignificant trend toward diminished total tau. 3 In addition, there was as significant decrease in temporal, medial temporal, and frontal composites of standard uptake value ratios (SUVR) on tau positron emission tomography (PET).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.